GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Evertec Inc. Common Stock (EVTC) [hlAlert]

Rating:
Buy EVTC
down 14.01 %

Evertec Inc. Common Stock (EVTC) rated Buy by BofA/Merrill

Posted on: Monday,  Sep 16, 2013  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Buy Evertec Inc. Common Stock (NYSE: EVTC) on 09/16/2013. Previously BofA/Merrill rated Buy Evertec Inc. Common Stock (NYSE: EVTC) on
05/07/2013., when the stock price was $20.76. Since then, Evertec Inc. Common Stock has lost 14.02% as of 01/14/2016's recent price of $17.85.
If you would have followed the previous BofA/Merrill's recommendation on EVTC, you would have lost 14.01% of your investment in 982 days.

Evotec AG (Evotec) is a drug discovery and development company focused on small molecule therapeutics. Evotec is developing treatments for diseases in the areas of neuroscience, pain, and inflammation. Evotec?s portfolio comprises five clinical drug candidates: EVT 101, a subtype selective NMDA receptor antagonist with potential for the treatment of Alzheimer?s disease, pain and depression, EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 302, a MAO-B inhibitor in development for smoking cessation, a P2X7 antagonist for the treatment of inflammatory diseases, and a small molecule vanilloid receptor (VR1) antagonist for the treatment of pain in partnership with Pfizer. Evotec?s late stage preclinical research programs focus on EVT 103, a back-up compound to EVT 101, H3 antagonists for the treatment of cognitive disorders and/or sleep, as well as antagonists for the purinergic receptor P2X3 for the treatment of pain.

BofA/Merrill
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/16/2013 8:25 AM Buy
None
23.50
as of 12/13/2013
1 Week up  7.54 %
1 Month up  1.57 %
3 Months down  -2.55 %
1 YTD down  -4.17 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/7/2013 8:25 AM Buy
None
20.76

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy